SCHEMBL16201446

SCHEMBL16201446

CCCN(C)Cc1c[nH]nc1-c1cccc(OC(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 3/20 0.42
PRMT8 Q9NR22 3/20 0.42
PRMT3 O60678 2/20 0.42
CARM1 Q86X55 2/20 0.42
PRMT1 Q99873 2/20 0.42
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PTPN5 P54829 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
SLC13A5 Q86YT5 1/20 0.33
WDR5 P61964 1/20 0.33
HTR6 P50406 1/20 0.33
CYP2C8 P10632 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201273 0.90 PRMT1 (0.55) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16201387 0.87 GAA (0.41) PDE4B
SCHEMBL16201332 0.86 PRMT1 (0.51) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16201382 0.82 SMN1; SMN2 (0.41) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16201455 0.82 KDM5A (0.38) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16125848 0.81 PRMT6 (0.36) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16201410 0.81 NOTUM (0.38) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16201373 0.81 STK4 (0.44) PRMT6PRMT8CARM1PRMT1PDE4B
SCHEMBL16201329 0.81 NPC1 (0.44) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16201341 0.80 MOK (0.37) PRMT6PRMT8PRMT3CARM1PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT6 4/4885PRMT8 6/4885PRMT3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.